Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients With Lennox-Gastaut Syndrome

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clemizole (Primary)
Indications Lennox-Gastaut syndrome
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms ELEGANSE
Sponsors Epygenix Therapeutics

Most Recent Events

26 Aug 2025 According to a Harmony Biosciences media release, company will present data from two phase III trials at the 36th International Epilepsy Congress (IEC) being held 30 - Aug - 3 Sep 2025, at the Lisbon Congress Centre in Lisbon, Portugal.
10 Apr 2025 Planned number of patients changed from 24 to 260.
10 Apr 2025 Planned End Date changed from 1 Feb 2025 to 1 Nov 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com